title: Angiotensin-converting Enzyme Inhibitor Angioedema Requiring Admission to an Intensive Care Unit.
abstract: OBJECTIVE
  The purpose of this study was to review consecutive cases of angiotensin-converting enzyme (ACE) inhibitor angioedema admitted to an intensive care unit.
  
  
  METHODS
  Fifty subjects with ACE-inhibitor angioedema admitted from 1998-2011 were reviewed.
  
  
  RESULTS
  All 50 subjects were men, 62.8 ± 8.4 years of age, 76% African Americans. Fifteen (30%) required ventilatory support and 2 (4%) required tracheostomy. Over half (56%) had taken ACE inhibitors for over a year. Logistic regression identified dyspnea and tongue involvement with the need for ventilatory support (P < .01). Hypercapnia (PaCO2 = 45.2 ± 6.7; P = 0.046) also identified patients needing ventilatory support.
  
  
  CONCLUSIONS
  Ventilatory support was provided for about one-third of those with ACE inhibitor-associated angioedema. Angioedema can occur even after extended use. Dyspnea and tongue involvement identified patients requiring ventilatory support.
authors.affiliation: Pulmonary and Critical Care Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California, Los Angeles. Electronic address: guy.soohoo@va.gov.
authors.forename: Guy W
authors.initials: GW
authors.lastname: Soo Hoo
authors.affiliation: Allergy and Immunology Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California, Los Angeles.
authors.forename: Henry K
authors.initials: HK
authors.lastname: Lin
authors.affiliation: Allergy and Immunology Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California, Los Angeles.
authors.forename: Imran
authors.initials: I
authors.lastname: Junaid
authors.affiliation: Allergy and Immunology Section, Department of Medicine, Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine, University of California, Los Angeles.
authors.forename: William B
authors.initials: WB
authors.lastname: Klaustermeyer
mesh_terms: D017677:Age Distribution; D000368:Aged; D000799:Angioedema / Q000139:chemically induced* / Q000401:mortality / Q000628:therapy*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D016001:Confidence Intervals; D003422:Critical Care / Q000379:methods / Q000706:statistics & numerical data; D005500:Follow-Up Studies; D017052:Hospital Mortality; D006801:Humans; D015994:Incidence; D007362:Intensive Care Units / Q000706:statistics & numerical data*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010343:Patient Admission / Q000706:statistics & numerical data; D012121:Respiration, Artificial / Q000379:methods; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D015996:Survival Rate; D014139:Tracheostomy / Q000379:methods
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors
keywords: Angioedema; Angiotensin-converting enzyme inhibitor; Respiratory failure